Will the price of ixazomib change in 2025?

Since Ixazomib was approved for multiple myeloma, its unique oral proteasome inhibition mechanism and convenient use have made it one of the important targeted drugs widely used in maintenance therapy. At present, the original drug of ixazomib has been officially launched in mainland China and has been included in the Category B medical insurance catalog. Common specifications include 4mg, 3mg and 2.5mg capsules, each box is packed with 3 capsules. Calculated based on market quotations, before medical insurance reimbursement, the price per box is generally around 10,000 yuan, especially the 4mg specification, which has the highest price, which puts a heavy financial burden on ordinary patients. Since the drug is still under patent protection, it is difficult for the price to drop significantly in the short term. However, with the gradual advancement of the national centralized purchasing policy and the improvement of the dynamic adjustment mechanism of the medical insurance catalog, there will be some room for downward price growth in the future.

Compared with China, the price of ixazomib in overseas markets such as the United States is higher. The price of each box can reach more than 10,000 US dollars. It is almost unaffordable without insurance payment. This has also prompted patients to turn their attention to the more cost-effective overseas generic drug market.

Currently, countries including Laos have launched generic versions of ixazomib, whose pharmaceutical ingredients are basically the same as the original drug. The common Laos version is 4 mg × 3 capsules/box, each box only costs about RMB 900, and the price advantage is obvious. Judging from market development trends, the global use of ixazomib is changing from centralized procurement to "coexistence of multiple channels." In the future, as generic drugs continue to enter the markets of more countries, its overall selling price and difficulty in obtaining it are expected to be further reduced, especially for domestic low- and middle-income patients, providing more accessible options. But at the same time, it is also necessary to strengthen medication guidance and drug source supervision to ensure the safety and compliance of generic drugs in quality, storage, transportation and other aspects.

Reference materials:https://www.ninlaro.com/